HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, May 20, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced it will present preclinical data from the Company's interferon...